# Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

> **NCT02536404** · PHASE2 · COMPLETED · sponsor: **Arena Pharmaceuticals** · enrollment: 118 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02536404
- **Lead sponsor:** Arena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-25
- **Primary completion:** 2018-11-01
- **Final completion:** 2018-11-01
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536404, "Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02536404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*